2025
Society of Family Planning Clinical Recommendation: Prevention of infection after abortion and pregnancy loss
Cheng T, Kumar N, Laursen L, Achilles S, Reeves M, Atrio S. Society of Family Planning Clinical Recommendation: Prevention of infection after abortion and pregnancy loss. Contraception 2025, 148: 110895. PMID: 40154660, DOI: 10.1016/j.contraception.2025.110895.Peer-Reviewed Original ResearchConceptsManagement of pregnancy lossCenters for Disease Control and Prevention guidelinesUniversal antibiotic prophylaxisPrevention of infectionAntibiotic prophylaxisProcedural abortionPregnancy lossGrade 1CGrade 1bMedical managementGrade 1ASingle doseManagement of early pregnancy lossMedical management of early pregnancy lossSingle dose of doxycyclineRoutine antibiotic prophylaxisProcedural managementSecond-line optionUS Preventive Services Task Force recommendationsRisk of side effectsDose of doxycyclineEarly pregnancy lossClinical care of patientsDiagnosis of gonorrheaInsufficient evidence
2024
Supervised Disulfiram Should Be Considered First-line Treatment for Alcohol Use Disorder
Holt S. Supervised Disulfiram Should Be Considered First-line Treatment for Alcohol Use Disorder. Journal Of Addiction Medicine 2024, 18: 614-616. PMID: 39150091, DOI: 10.1097/adm.0000000000001345.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAlcohol use disorderSupervised disulfiramUse disorderAlcohol use disorder treatmentPrevalence of alcohol use disordersFDA-approved medicationsRandomized Controlled TrialsFirst-line interventionBehavioral interventionsDouble-Blind Randomized Controlled TrialApproved medicationsDisulfiramOpen-label randomized controlled trialSecond-line optionFirst-line treatmentNational treatment guidelinesDisordersTherapeutic resourcesEfficacy dataMedicationTreatment guidelinesAddictionControlled TrialsInterventionPatient preferencesEfficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series
Yamamoto N, Tolcher A, Hafez N, Lugowska I, Ramlau R, Macarulla T, Geng J, Li J, Teufel M, Märten A, LoRusso P. Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series. OncoTargets And Therapy 2024, 17: 267-280. PMID: 38567193, PMCID: PMC10986405, DOI: 10.2147/ott.s440979.Peer-Reviewed Original ResearchBiliary tract cancerAdvanced biliary tract cancerAdverse eventsDose reduction due to adverse eventsBiliary tract cancer casesChemotherapy plus immunotherapyPhase Ia/Ib trialPD-1 inhibitorsSecond-line optionAnti-tumor activityStable diseasePartial responsePD-1Treatment discontinuationCase seriesSafety profilePatientsImprove outcomesMolecular heterogeneityCancerMDM2-p53DiseaseImmunotherapyDoseEfficacy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply